Cost-Effectiveness Compared for Metastatic Melanoma Treatments

This article originally appeared here.
Share this content:
Cost-Effectiveness Compared for Metastatic Melanoma Treatments
Cost-Effectiveness Compared for Metastatic Melanoma Treatments

MONDAY, March 6, 2017 (HealthDay News) -- For patients with BRAF wild-type metastatic melanoma, first-line pembrolizumab (PEM) every three weeks followed by second-line ipilumumab (IPI), or first-line nivolumab (NIVO) followed by IPI, are the most cost-effective strategies, according to a study published online Feb. 21 in the Journal of Clinical Oncology.

Christine G. Kohn, Pharm.D., from the University of Saint Joseph School of Pharmacy in Hartford, Conn., and colleagues compared the cost-effectiveness of different strategies for sequencing novel agents for advanced melanoma treatment. A Markov model was developed using a U.S.-payer perspective and lifetime horizon to estimate costs and quality-adjusted life-years (QALYs) for treatment sequences with first-line NIVO, IPI, NIVO + IPI, and PEM every two weeks, and PEM every three weeks.

The researchers found that, compared with dacarbazine followed by IPI then NIVO, or IPI followed by NIVO, PEM every three weeks followed by second-line IPI was more effective and less costly. NIVO followed by IPI produced an incremental cost-effectiveness ratio of $90,871/QALY, and first-line NIVO +IPI followed by carboplatin plus paclitaxel chemotherapy resulted in an incremental cost-effectiveness ratio of $198,867/QALY, compared with first-line dacarbazine treatment.

"For patients with treatment-naive BRAF wild-type advanced melanoma, first-line PEM every three weeks followed by second-line IPI or first-line NIVO followed by second-line IPI are the most cost-effective, immune-based treatment strategies for metastatic melanoma," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

Non-Nutritive Sweeteners Don't Up Blood Glucose Levels

Non-Nutritive Sweeteners Don't Up Blood Glucose Levels

Concentration of NNSs decreases gradually over the course of observation after consumption

Laws Allowing Service Denial to Sexual Minorities Tied to Distress

Laws Allowing Service Denial to Sexual Minorities Tied ...

Laws permitting denial of services linked to increase in mental distress among sexual minorities

Antidepressant Prescribing Linked to Lasting Weight Gain

Antidepressant Prescribing Linked to Lasting Weight Gain

Risk of weight gain remained increased during at least six years of follow-up